Preconditioning approach in stem cell therapy for the treatment of infarcted heart

Khawaja Husnain Haider, Muhammad Ashraf

Research output: Chapter in Book/Report/Conference proceedingChapter

17 Citations (Scopus)

Abstract

Nearly two decades of research in regenerative medicine have been focused on the development of stem cells as a therapeutic option for treatment of the ischemic heart. Given the ability of stem cells to regenerate the damaged tissue, stem-cell-based therapy is an ideal approach for cardiovascular disorders. Preclinical studies in experimental animal models and clinical trials to determine the safety and efficacy of stem cell therapy have produced encouraging results that promise angiomyogenic repair of the ischemically damaged heart. Despite these promising results, stem cell therapy is still confronted with issues ranging from uncertainty about the as-yet-undetermined "ideal" donor cell type to the nonoptimized cell delivery strategies to harness optimal clinical benefits. Moreover, these lacunae have significantly hampered the progress of the heart cell therapy approach from bench to bedside for routine clinical applications. Massive death of donor cells in the infarcted myocardium during acute phase postengraftment is one of the areas of prime concern, which immensely lowers the efficacy of the procedure. An overview of the published data relevant to stem cell therapy is provided here and the various strategies that have been adopted to develop and optimize the protocols to enhance donor stem cell survival posttransplantation are discussed, with special focus on the preconditioning approach.

Original languageEnglish (US)
Title of host publicationProgress in Molecular Biology and Translational Science
PublisherElsevier B.V.
Pages323-356
Number of pages34
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Publication series

NameProgress in Molecular Biology and Translational Science
Volume111
ISSN (Print)1877-1173

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Therapeutics
Regenerative Medicine
Uncertainty
Cell Survival
Myocardium
Cell Death
Animal Models
Clinical Trials
Safety
Research

Keywords

  • Heart
  • Preconditioning
  • Stem cells
  • Survival
  • Transplantation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Haider, K. H., & Ashraf, M. (2012). Preconditioning approach in stem cell therapy for the treatment of infarcted heart. In Progress in Molecular Biology and Translational Science (pp. 323-356). (Progress in Molecular Biology and Translational Science; Vol. 111). Elsevier B.V.. https://doi.org/10.1016/B978-0-12-398459-3.00015-0

Preconditioning approach in stem cell therapy for the treatment of infarcted heart. / Haider, Khawaja Husnain; Ashraf, Muhammad.

Progress in Molecular Biology and Translational Science. Elsevier B.V., 2012. p. 323-356 (Progress in Molecular Biology and Translational Science; Vol. 111).

Research output: Chapter in Book/Report/Conference proceedingChapter

Haider, KH & Ashraf, M 2012, Preconditioning approach in stem cell therapy for the treatment of infarcted heart. in Progress in Molecular Biology and Translational Science. Progress in Molecular Biology and Translational Science, vol. 111, Elsevier B.V., pp. 323-356. https://doi.org/10.1016/B978-0-12-398459-3.00015-0
Haider KH, Ashraf M. Preconditioning approach in stem cell therapy for the treatment of infarcted heart. In Progress in Molecular Biology and Translational Science. Elsevier B.V. 2012. p. 323-356. (Progress in Molecular Biology and Translational Science). https://doi.org/10.1016/B978-0-12-398459-3.00015-0
Haider, Khawaja Husnain ; Ashraf, Muhammad. / Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Progress in Molecular Biology and Translational Science. Elsevier B.V., 2012. pp. 323-356 (Progress in Molecular Biology and Translational Science).
@inbook{12ef9b9881f145f9945fc3b091338fcf,
title = "Preconditioning approach in stem cell therapy for the treatment of infarcted heart",
abstract = "Nearly two decades of research in regenerative medicine have been focused on the development of stem cells as a therapeutic option for treatment of the ischemic heart. Given the ability of stem cells to regenerate the damaged tissue, stem-cell-based therapy is an ideal approach for cardiovascular disorders. Preclinical studies in experimental animal models and clinical trials to determine the safety and efficacy of stem cell therapy have produced encouraging results that promise angiomyogenic repair of the ischemically damaged heart. Despite these promising results, stem cell therapy is still confronted with issues ranging from uncertainty about the as-yet-undetermined {"}ideal{"} donor cell type to the nonoptimized cell delivery strategies to harness optimal clinical benefits. Moreover, these lacunae have significantly hampered the progress of the heart cell therapy approach from bench to bedside for routine clinical applications. Massive death of donor cells in the infarcted myocardium during acute phase postengraftment is one of the areas of prime concern, which immensely lowers the efficacy of the procedure. An overview of the published data relevant to stem cell therapy is provided here and the various strategies that have been adopted to develop and optimize the protocols to enhance donor stem cell survival posttransplantation are discussed, with special focus on the preconditioning approach.",
keywords = "Heart, Preconditioning, Stem cells, Survival, Transplantation",
author = "Haider, {Khawaja Husnain} and Muhammad Ashraf",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-398459-3.00015-0",
language = "English (US)",
series = "Progress in Molecular Biology and Translational Science",
publisher = "Elsevier B.V.",
pages = "323--356",
booktitle = "Progress in Molecular Biology and Translational Science",

}

TY - CHAP

T1 - Preconditioning approach in stem cell therapy for the treatment of infarcted heart

AU - Haider, Khawaja Husnain

AU - Ashraf, Muhammad

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Nearly two decades of research in regenerative medicine have been focused on the development of stem cells as a therapeutic option for treatment of the ischemic heart. Given the ability of stem cells to regenerate the damaged tissue, stem-cell-based therapy is an ideal approach for cardiovascular disorders. Preclinical studies in experimental animal models and clinical trials to determine the safety and efficacy of stem cell therapy have produced encouraging results that promise angiomyogenic repair of the ischemically damaged heart. Despite these promising results, stem cell therapy is still confronted with issues ranging from uncertainty about the as-yet-undetermined "ideal" donor cell type to the nonoptimized cell delivery strategies to harness optimal clinical benefits. Moreover, these lacunae have significantly hampered the progress of the heart cell therapy approach from bench to bedside for routine clinical applications. Massive death of donor cells in the infarcted myocardium during acute phase postengraftment is one of the areas of prime concern, which immensely lowers the efficacy of the procedure. An overview of the published data relevant to stem cell therapy is provided here and the various strategies that have been adopted to develop and optimize the protocols to enhance donor stem cell survival posttransplantation are discussed, with special focus on the preconditioning approach.

AB - Nearly two decades of research in regenerative medicine have been focused on the development of stem cells as a therapeutic option for treatment of the ischemic heart. Given the ability of stem cells to regenerate the damaged tissue, stem-cell-based therapy is an ideal approach for cardiovascular disorders. Preclinical studies in experimental animal models and clinical trials to determine the safety and efficacy of stem cell therapy have produced encouraging results that promise angiomyogenic repair of the ischemically damaged heart. Despite these promising results, stem cell therapy is still confronted with issues ranging from uncertainty about the as-yet-undetermined "ideal" donor cell type to the nonoptimized cell delivery strategies to harness optimal clinical benefits. Moreover, these lacunae have significantly hampered the progress of the heart cell therapy approach from bench to bedside for routine clinical applications. Massive death of donor cells in the infarcted myocardium during acute phase postengraftment is one of the areas of prime concern, which immensely lowers the efficacy of the procedure. An overview of the published data relevant to stem cell therapy is provided here and the various strategies that have been adopted to develop and optimize the protocols to enhance donor stem cell survival posttransplantation are discussed, with special focus on the preconditioning approach.

KW - Heart

KW - Preconditioning

KW - Stem cells

KW - Survival

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84865328681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865328681&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-398459-3.00015-0

DO - 10.1016/B978-0-12-398459-3.00015-0

M3 - Chapter

C2 - 22917238

AN - SCOPUS:84865328681

T3 - Progress in Molecular Biology and Translational Science

SP - 323

EP - 356

BT - Progress in Molecular Biology and Translational Science

PB - Elsevier B.V.

ER -